Analysts Set $8.00 Price Objective as Quince Therapeutics Reports $0.25 Q3 EPS Loss
Analysts hold a Moderate Buy consensus on Quince with an $8.00 average price objective, as DB Boral Capital lifted its target to $5.00 from $4.00. Shares opened at $2.69 following a Q3 EPS loss of $0.25, missing estimates by $0.05, with a one-year range of $0.72 to $4.55.
1. Pivotal Phase 3 NEAT Trial Poised for Readout
Quince Therapeutics is on track to report top-line data from its pivotal NEAT trial in Ataxia-Telangiectasia (A-T) by mid–first quarter 2026. The study enrolls 6–9 year-old patients and is powered at 90% to detect a clinically meaningful difference on its primary motor function endpoint. Design adjustments address limitations of prior studies, incorporating an extended treatment period and refined inclusion criteria. Regulatory agencies have provided written feedback on trial design, reinforcing Quince’s path toward potential approval for its lead asset, eDSP, in a rare pediatric neurodegenerative disorder with no currently approved therapies.
2. eDSP Targets a $1 Billion Orphan Market
Quince’s eDSP platform delivers chronic corticosteroid therapy via encapsulation in a patient’s own red blood cells, aiming to reduce systemic toxicity. The orphan market for A-T is estimated to exceed $1 billion annually. If approved, eDSP could become the first disease-modifying therapy for this indication. Quince’s AIDE technology and proprietary RCL processing system underpin eDSP’s differentiation, with automated, point-of-care drug encapsulation kits (EryKit) designed to ensure consistent dosing and streamline clinical adoption.
3. Analyst Consensus Reflects Moderate Buy Sentiment
Seven analysts covering Quince have established a consensus rating of Moderate Buy, with four Buy, one Strong Buy, one Hold and one Sell recommendation. The average twelve-month price objective stands at $8.00 based on the most recent broker reports. Notable rating actions include an increase in target by D. Boral Capital from $4.00 to $5.00 and Citigroup’s reiteration of a market outperform view on January 6th. This collective outlook underscores confidence in potential clinical success and commercial upside upon NEAT trial readout.
4. Institutional Interest and Recent Financial Metrics
Institutional investors hold approximately 30.75% of outstanding shares, with recent activity including a new $37,000 position by XTX Topco Ltd and a 158% increase by GSA Capital Partners LLP. Quince reported third-quarter EPS of –$0.25, missing consensus by $0.05 and driving an annual EPS forecast of –1.21. The company carries a market capitalization of $149.8 million, a negative P/E ratio of 2.22, and a beta of 1.15, reflecting both its developmental-stage risk profile and potential for value inflection upon clinical validation.